TRDA · Entrada Therapeutics, Inc.

Track TRDA — free

$5.42 -0.06 (-1.09%) At close · Oct 6

Russell 2000 member Rebalance outlook locked

Market Cap

$239.85M

38.94M

Volume · Oct 6 315.92K Avg daily vol (3M) 363.01K

Up next

Latest filing: 10-Q

filed Aug 5, 2026

Q1 2026 earnings call transcript

call held May 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$4.69M

Trailing 12 months

Net income (TTM)

−$165.78M

Trailing 12 months

Revenue growth YoY

-53.9%

Year over year

Operating margin

-3,767.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.1%

Year over year · more shares

Price change (1Y)

-8.7%

Trailing year

Short interest

7.0%

Latest settlement · 8.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15 · calm Equity put/call 0.57

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −42%

below

Price vs 50-day avg −21%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −28%

trailing

6-month return −61%

trailing

YTD return −47%

this year

Relative strength −73%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $7 › 200d $9 — 200d above 50d

Institutional flow Distributing

2 of 128 funds reported for Sep 30 · net -16 sh shares

Insider flow Distributing

Net -$10.3M over 90 days · 100% sells

Short interest Rising

7.05% of float · ▲ +17.0% MoM · 8.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

128 holders — near 3-yr high, broad support

Squeeze score 65

elevated · 0–100

Fundamentals

Poor

Revenue growth −88%

Y/Y

EPS growth −307%

Y/Y

Free cash flow $-129.6M

Quant / Vol

risk profile

Very High

Volatility 86%

annualized · 1-yr

Max drawdown −66%

past year

ATR 8.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−42% Bearish

Price vs 50-day avg

−21% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $7 › 200d $9 — 200d above 50d

Institutional flow Distributing

2 of 128 funds reported for Sep 30 · net -16 sh shares

Insider flow Distributing

Net -$10.3M over 90 days · 100% sells

Short interest Rising

7.05% of float · ▲ +17.0% MoM · 8.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

128 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $5 · 0% Range high $16

vs 200-day avg -42% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TRDA Entrada Therapeutics, Inc. this stock	$239.85M	-47.3%	-87.9%	—	7.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+10.8%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.3%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+535.7%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

128

% held: 74.7%
Reported: 2 of 128
Top holder: BAKER BROS. ADVISORS LP

Held Float

View

Held by Funds

Fund positions

139

View

Short & Settlement

Short Interest Rising

Shares short

2.7M

Days to cover: 8.1d
Change: +398.3K sh

View

Short Volume

Short vol %

53%

As of: Oct 6, 2026

Short Total

View

Fails to Deliver

FTD shares

279

Value: $2.0K
As of: Sep 4, 2026

View

Off-Exchange

Off-exchange %

44.9%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$10.3M

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Financials

Revenue (FY)

$25.4M

Net income (FY): $-143.8M
EPS diluted: $-3.47

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 10

View

Proposed Sales

Value

$2.2M

Shares: 331.2K
Filed: Jul 30, 2026

View

Exempt Offerings

Offering

$116.2M

Filed: Apr 13, 2021

View

Earnings & Events

Webcasts

Last webcast

May 7, 2026

View

Performance

	5D	20D	120D	MTD	YTD
TRDA	-13.4%	-27.9%	-61.3%	-14.7%	-47.3%
SPY	+2.0%	+1.7%	+11.3%	+2.2%	+14.3%
vs SPY	-15.4%	-29.6%	-72.6%	-16.8%	-61.5%

Key facts CIK 1689375 CUSIP 29384C108 13F (30d) 4 filings 4 filers Visit website Investor relations

TRDA · Entrada Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance